Loading... (0%)
About liver disease

GENFIT: A GLOBAL APPROACH TO THE DISEASE

Facilitate identification and referrals of NASH patients.
LEARN MORE
Phase 3 study of elafibranor in NASH with fibrosis is currently enrolling patients around the world.
LEARN MORE

COMPANY LIFE

GENFIT is a biopharmaceutical company dedicated to high unmet medical needs.
caste-ridden
Find out our about current job opportunities or submit your spontaneous application explaining your project.
LEARN MORE

DOCUMENTATION

The NASH Education Program™

Health prevention, medical education, dissemination of relevant information related to NASH disease

(855) 310-7601
Press releases
  • 2018 Half-Year Results: Cash Position at End of Period at €238M and Significant Advances in the Clinical Development of Elafibranor
    09/24/2018
  • GENFIT: Major Milestone achieved with full recruitment of the Phase 2 trial evaluating elafibranor in PBC
    08/28/2018
  • GENFIT: New Preclinical Data Shows Elafibranor Inhibits Development of NAFLD/NASH-Related Cancer
    06/27/2018
Events
47740c785056773023caf611bb607fb12222222222222222222222222222